Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs AMCINONIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, eczema, contact dermatitis)
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted renally.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Approximately 95–99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Apparent volume of distribution is about 0.14–0.3 L/kg, indicating extensive tissue distribution.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Topical: Bioavailability is high but variable due to skin barrier; systemic absorption ranges from 0.5% to 2% with intact skin, higher with occlusion or inflamed skin. Intralesional: Complete systemic absorption.
No dose adjustment required. Topical use with minimal systemic absorption.
No adjustment required for topical use. Systemic absorption is minimal.
No dose adjustment required. Topical use with minimal systemic absorption.
No adjustment required for topical use. Systemic absorption is minimal.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Use lowest effective dose for shortest duration. Apply sparingly to small areas. Avoid use in children <2 years of age. For children ≥2 years: apply thin film once or twice daily. Limit treatment to 5-7 days.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
Use lowest effective dose for shortest duration. Apply sparingly due to thinner skin and increased systemic absorption risk. Avoid use on large areas or under occlusive dressings.
No FDA black box warning.
None.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Systemic absorption with prolonged use or large areas may cause HPA axis suppression, Cushing's syndrome, or hyperglycemia.,Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections.,Avoid use on face, axillae, or groin unless directed; use caution in patients with impaired skin integrity.,Not recommended for diaper dermatitis or for use under occlusive dressings.
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to amcinonide or any component of the formulation.,Untreated bacterial, viral, or fungal infections at the application site.,Topical application for ophthalmic or intravaginal use.
No known food interactions with topical Aclovate.
No known food interactions. Avoid excessive ingestion of corticosteroids systemically, but topical application does not require dietary restrictions.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic administration, but the risk with topical application is low due to minimal systemic absorption. However, prolonged or large-area use may increase systemic absorption and potential fetal risk. First trimester: Avoid unless clearly needed. Second and third trimesters: Use with caution, avoiding extensive areas, prolonged use, or occlusive dressings.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
No data available on excretion into breast milk. Systemic absorption after topical application is minimal but may occur with prolonged or large-area use. Caution should be exercised as a risk to the infant cannot be excluded. Use only if clearly needed and apply to smallest area for shortest duration. M/P ratio: Not established.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No disease-specific pharmacokinetic changes for amcinonide. Dosing adjustments are not generally recommended, but consider using the lowest effective dose, smallest area, and shortest duration to minimize systemic absorption. Avoid occlusive dressings and use on large areas or broken skin due to increased absorption.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
Amcinonide is a high-potency topical corticosteroid, typically used for short-term treatment of corticosteroid-responsive dermatoses. Due to its potency, it should be applied sparingly and not used under occlusion unless directed. Avoid use on face, groin, or axillae due to increased risk of skin atrophy and systemic absorption. Monitor for local adverse effects such as striae, hypopigmentation, or rosacea-like dermatitis. Systemic absorption can occur with extensive use, particularly in children or when applied to large body surface areas.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Apply a thin layer to affected skin only; do not use on broken or infected skin unless prescribed.,Wash hands after application unless treating hands.,Do not cover treated area with bandages or plastic wrap unless instructed by your doctor.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use for longer than prescribed; overuse can lead to skin thinning and other side effects.,Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant.
No interactions on record
"Magnesium trisilicate, an antacid, can significantly reduce the oral bioavailability of Amcinonide, a topical corticosteroid, when administered concurrently. The mechanism involves magnesium ions chelating with the corticosteroid or altering gastrointestinal pH, thereby impairing dissolution and absorption of Amcinonide. This interaction may lead to reduced efficacy of Amcinonide therapy, particularly when higher systemic exposure is required for therapeutic effect."
"Concurrent use of topical corticosteroids like Amcinonide and systemic acetylcholinesterase inhibitors such as Pyridostigmine may potentiate adverse effects, particularly electrolyte disturbances and cardiovascular events. Pyridostigmine enhances cholinergic activity, which can lead to increased gastrointestinal motility and bronchial secretions, while Amcinonide's mineralocorticoid activity can cause sodium and water retention, aggravating fluid overload and hypertension. This interaction is clinically significant in patients with myasthenia gravis receiving Pyridostigmine, as corticosteroid-induced hypokalemia may worsen muscle weakness."
"The combination of leflunomide, an immunomodulator that inhibits dihydroorotate dehydrogenase and suppresses lymphocyte proliferation, with amcinonide, a potent topical corticosteroid, may result in additive immunosuppression, increasing the risk of serious infections, including bacterial, viral, fungal, and opportunistic infections. Systemic absorption of topical corticosteroids can occur, especially with prolonged use on large areas, damaged skin, or under occlusive dressings, potentiating adrenal suppression and other systemic corticosteroid effects. Patients receiving both agents require careful monitoring for signs of infection, adrenal insufficiency, and other adverse effects related to enhanced immunosuppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs AMCINONIDE, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. AMCINONIDE is a Topical Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and AMCINONIDE depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of AMCINONIDE is: Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and AMCINONIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . AMCINONIDE is classified as Category C. Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.